The FDA has approved a new agent for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established ASCVD as an adjunct to diet and maximally tolerated statin therapy.
An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.
